Telesis Bio Balance Sheet Health
Financial Health criteria checks 4/6
Telesis Bio has a total shareholder equity of $3.9M and total debt of $5.8M, which brings its debt-to-equity ratio to 150.7%. Its total assets and total liabilities are $24.7M and $20.9M respectively.
Key information
150.7%
Debt to equity ratio
US$5.84m
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.51m |
| Equity | US$3.87m |
| Total liabilities | US$20.86m |
| Total assets | US$24.74m |
Recent financial health updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Financial Position Analysis
Short Term Liabilities: TBIO's short term assets ($8.1M) exceed its short term liabilities ($6.6M).
Long Term Liabilities: TBIO's short term assets ($8.1M) do not cover its long term liabilities ($14.2M).
Debt to Equity History and Analysis
Debt Level: TBIO's net debt to equity ratio (34.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TBIO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TBIO has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: TBIO is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:14 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Telesis Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brandon Couillard | Jefferies LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Douglas Schenkel | TD Cowen |